I was reviewing a client’s insulin administration. She was administering Levemir (insulin detemir), 60 units, with a FlexPen. She said that she just dialed the dose to the maximum it would allow her as she knew it only would dial to 60 units. She did not confirm the dose visually. Although …

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP Diabetic ketoacidosis (DKA) is a state of severe uncontrolled diabetes caused by insulin deficiency. It is characterised by hyperglycaemia, hyperketonaemia and metabolic acidosis, and has been somewhat arbitrarily divided into mild, moderate and severe based upon biochemical and clinical features (Table 12.1)….

FDA Approves New Once-Weekly GLP-1  See this week’s Item #1.

Trulicity™ (dulaglutide) Trulicity (dulaglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) just approved by the FDA that offers adults with type 2 diabetes once-weekly dosing in the Trulicity pen, which has a pre-attached, hidden needle and requires no reconstitution. Prescribing Information   

Patient Handout: Your Job Your Rights (PDF)  Important information for your patients. This updated four-panel brochure addresses the issues of discrimination based on diabetes in the workplace. It outlines the laws, personal rights, federally mandated accommodations, and how to address discrimination. Know Your Rights (English) Know Your Rights (Spanish)    

Researchers found little change in the prevalence and incidence of diabetes between 2008 and 2012, following drastic increases in both numbers between 1990 and 2008. "We are now for the first time showing that (those rates are) slowing down," said Dr. Ann Albright, who directs the Division of Diabetes Translation …

A six-year study of people with type 2 diabetes found that intensively lowering blood pressure had a long-lasting effect in preventing heart attacks, strokes and deaths. But intensive blood sugar control didn’t produce those benefits, the researchers found. For the study, investigators followed nearly 8,500 participants of a completed diabetes …

Data presented at the European Association for the Study of Diabetes meeting revealed a fixed-dose insulin degludec/liraglutide combination resulted in greater blood glucose control in type 2 diabetes patients compared with either monotherapy. The insulin degludec/liraglutide combination treatment resulted in a greater proportion of subjects with blood glucose values within …

Dulaglutide (Trulicity) is approved as a once-weekly injection for the treatment of type 2 diabetes…. Dulaglutide is a member of the glucagon-like peptide (GLP-1) receptor agonist class, along with liraglutide, exenatide, and albiglutide. The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity) as a once a week injection …

A large study in the UK looked at the long-term effects of GLP-1 and DPP-4 therapy on patients’ risk of congestive heart failure….